

Pneumococcal Vaccination Recommendations for Children¹ and Adults by Age and/or Risk Factor

Routine Recommendations

for Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)

For children age 2 months and older	Administer PCV13 series to all children beginning at age 2 months, followed by doses at 4 months, 6 months, and 12–15 months (booster dose).	For adults age 65 years and older	Administer 1-time dose to PCV13-naïve adults at age 65 years, followed by a dose of PPSV23 12 months later.
--	--	--	---

Risk-based Recommendations

People with Underlying Medical Conditions or Other Risk Factors

Risk Group	Underlying medical condition or other risk factor	PCV13			PPSV23	
		Administer PCV13 doses needed to complete series to children through age 71 months	Administer 1 dose to PCV13-naïve children age 6 through 18 years	Administer 1 dose to PCV13-naïve adults age 19 through 64 years	Administer 1 dose of PPSV23 at age 2 through 64 years	Administer a second dose of PPSV23 5 years after first dose if age younger than 65 years
Immuno-competent	Chronic heart disease ²	X			X	
	Chronic lung disease ³	X			X	
	Diabetes mellitus	X			X	
	Cerebrospinal fluid leak	X	X	X	X	
	Cochlear implant	X	X	X	X	
	Alcoholism				X	
	Chronic liver disease, cirrhosis				X	
	Cigarette smoking (≥19 yrs)				X	
Functional or anatomic asplenia	Sickle cell disease/other hemoglobinopathy	X	X	X	X	X
	Congenital or acquired asplenia	X	X	X	X	X
Immuno-compromised	Congenital or acquired immunodeficiency ⁴	X	X	X	X	X
	HIV	X	X	X	X	X
	Chronic renal failure	X	X	X	X	X
	Nephrotic syndrome	X	X	X	X	X
	Leukemia	X	X	X	X	X
	Lymphoma	X	X	X	X	X
	Hodgkin disease	X	X	X	X	X
	Generalized malignancy	X	X	X	X	X
	Iatrogenic immunosuppression ⁵	X	X	X	X	X
	Solid organ transplant	X	X	X	X	X
	Multiple myeloma	X	X	X	X	X

¹ For PCV13 vaccination of healthy children, see “Recommendations for Pneumococcal Vaccine Use in Children” at www.immunize.org/catg.d/p2016.pdf.

² Particularly cyanotic congenital heart disease and cardiac failure in children; including congestive heart failure and cardiomyopathy in all ages; excluding hypertension in adults.

³ Including asthma in children if treated with high-dose oral corticosteroid therapy, as well as chronic obstructive pulmonary disease (COPD), emphysema, and asthma in adults.

⁴ Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).

⁵ Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.

Technical content reviewed by the Centers for Disease Control and Prevention

Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org

www.immunize.org/catg.d/p2019.pdf • Item #P2019 (11/15)